Why Farbe Firma is the Leading Injectable Manufacturer in Samoa Last Updated: 18 September 2026 TL;DR: Samoa - the independent state, not American Samoa - has no operating medicines registration system, and the Ministry of Health says so in its own current policy: "No product evaluation, registration or listing system exists at the moment." What exists on the statute book is a narrow new-drug gate in the Drugs Act 1967. The real gates are the Essential Medicines List, a Central Warehouse contract, a Samoan importer, and Customs. Key Takeaways The Government of Samoa states in its National Medicines Policy and Plan of Action FY2023/24 - FY2027/28 that no product evaluation, registration or listing system exists. That is an absence quoted from the Ministry itself, not a "not found" on our side. Section 14 of the Drugs Act 1967 is unrepealed and does require approval before a "new drug" is imported. But "new drug" means a substance not previously used in Samoa, so an established generic injectable appears to sit outside it. The 90 days in section 14(3) is a standstill on sale, not an approval timeline. We found no Samoan list of recognised or stringent regulatory authorities. The closest text is a 2008 policy sentence naming authorities "such as TGA and FDA" - illustrative, not closed. India is unnamed, and nothing says Indian approval is refused. India's CDSCO appears on WHO's List of transitional WLAs, but the scope column designates it for vaccines only. A tender clause asking for a stringent authority for a medicine is not satisfied by CDSCO, and the Global Fund's definition excludes it too. Introduction: What an Injectable Manufacturer in Samoa Actually Has to Clear One clarification belongs at the top. Samoa here means the Independent State of Samoa, capital Apia, currency the Samoan tala. It is not American Samoa, a United States territory whose medicines are governed by the US FDA. Search results and health-statistics tables conflate the two constantly. A supplier who plans around American Samoan law plans around the wrong country's law. The second point is stranger. Most exporter guides explain how to register a product. For Samoa that framing has no object: the Ministry of Health's current National Medicines Policy and Plan of Action FY2023/24 - FY2027/28 states plainly that no product evaluation, registration or listing system exists at the moment, adding that Samoa applies reliance in the selection of medicines during procurement. Be precise about the evidential weight of that: it is not that we searched and found no register; the Ministry which would run one says there is none. What Sets a World-Class Injectable Manufacturer in Samoa Apart What separates a serious supplier here is refusing to over-read that vacuum, because there is law on the books. The governing instrument is the Drugs Act 1967, commenced 24 July 1967, revised as at 31 December 2023. It was the Food and Drugs Act 1967 until the Food Act 2015 removed the food references; older indexes carry the outdated title. Section 14 provides that no person may import or manufacture a new drug unless approved by the Chief Executive Officer of the Ministry of Health - not a chief pharmacist, not a medicines board. The definitional limit is the whole commercial point. A "new drug" is a substance which has not previously been used in Samoa. The trigger is novelty to the country, not to the supplier or the world, so a molecule already in Samoan use appears to fall outside section 14 altogether - a reading worth confirming with the Ministry rather than assuming. Note also what the section 14 dossier list does not ask for: no GMP certificate, no Certificate of Pharmaceutical Product, no bioequivalence, no site master file. Whether regulations under section 40 add any we could not establish either way. Quality Systems Behind Every Batch Shipped to Samoa Farbe Firma manufactures sterile injectables under WHO-GMP certification at ISO Class 5 aseptic filling in Gujarat, India, with in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A/Q1B stability work. Every batch ships with a certificate of analysis traceable to retained samples, and we prepare CTD and ACTD dossiers as standard for the 30+ countries we export to. The honest word in a Samoan context: nothing in Samoan law we could find requires a WHO-GMP certificate. It is a buyer-facing and donor-facing credential here, not a legal precondition. Documentation still matters. Samoa participates in the Pacific Medicine Testing Programme, under which Australia's Therapeutic Goods Administration laboratories test five products per country per year free of charge - post-market surveillance, not pre-market assessment. Meanwhile section 12 of the Drugs Act deems the person the label identifies as manufacturer or importer liable for a breach unless they prove otherwise. A supplier enters with no registration to shelter behind, judged by an Australian laboratory, carrying reverse-onus label liability. Planning a Samoa entry, or weighing a national route against a regional or donor-funded one? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Samoa for Global Buyers If entry is not rationed by dossier review, it is rationed by four other things, and those are where we put the effort. First, the Samoa Essential Medicines List, 4th Edition, July 2022, of about 170 medicines - a selection list, not a market authorisation. Second, the Ministry's Pharmaceutical Warehouse, opened in 2016 and also called the Central Warehouse, running on mSupply and procuring through framework contracts. Third, a Samoan importer or pharmacy supervised by a registered pharmacist. Fourth, Customs. The counterparty question is unusual and favourable. The Government states that it currently finances 100 per cent of the medicine needs of the public sector, so a supplier deals with a paying sovereign customer rather than a donor - though the same policy concedes it cannot pay suppliers on time, and states an intention to blacklist suppliers for untimely delivery. Donations from WHO, UNICEF, UNFPA and bilateral donors including China, India and Australia sit alongside that. We will publish no donor-versus-commercial split and no market size: the Government has not assessed its own market. Two structural facts read together. Samoa's policy quotes a World Bank assessment that Samoa, like all Pacific island countries, has little alternative other than to pay prices significantly above WHO median prices, and spends less on pharmaceuticals than its disease burden warrants. And the Government commits to using procurement to grow the Samoan private pharmaceutical sector. Both point the same way: partner with a local importer rather than sell around one. Local manufacture is no competing threat - local production is not on the agenda. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my injectable product with a Samoan medicines authority? On the Government's own account there is no registration system to register with. The qualification is section 14 of the Drugs Act 1967, which still requires approval by the Chief Executive Officer before a new drug is imported - "new drug" meaning one not previously used in Samoa. For an established generic molecule that gate appears not to apply, but confirm it with the Ministry. Is India on a Samoan list of approved countries or recognised regulators? No such list was found in any Samoan instrument; we looked in the Drugs Act 1967, the Pharmacy Act 2007 and the Ministry's legislation index. The nearest text is a 2008 policy sentence about medicines "internationally recognized by authorities such as TGA and FDA" - note it names the US FDA, not New Zealand's Medsafe, and that "such as" makes it illustrative. India is unnamed, but absence from a non-exhaustive example is not exclusion. Does CDSCO approval count as a stringent or WHO-Listed authority for Samoa? Not for a medicine, and this is a trap we would rather you heard from us. CDSCO appears on WHO's List of transitional WLAs, but the scope column designates it for vaccines only; other authorities in the same table carry "Medicines" and India does not. Separately, the Global Fund's stringent-authority definition is limited to ICH members and observers before 23 October 2015, excluding CDSCO and leaving WHO prequalification or the Expert Review Panel. Neither Samoa nor India is a PIC/S member. What dossier format, fees and timelines should I budget for in Samoa? We can give no fee schedule, no review timeline and no prescribed dossier format, because none was found - a "not found" rather than a proven absence, partly explained by there being no registration procedure for a format to attach to. Never treat the 90 days in section 14(3) as an approval timeline: it is a standstill on sale, with no decision deadline and no deemed approval. We supply CTD and ACTD regardless. What should a sterile injectable supplier be most careful about in Samoa? Presentation design, and we say that with care rather than as a sales angle. Samoa's 2019 measles epidemic killed more than eighty people, most of them children under four; reported tolls differ by cut-off date, 81 as at 28 December 2019 against 83 in total, and we are not choosing between them. It followed a 2018 incident in which two children died after MMR was reconstituted with an expired anaesthetic instead of sterile water. The vaccine was cleared: the failure was handling at the point of care, not manufacture. Diluent pairing, labelling, look-alike vial risk and lot traceability are therefore matters on which a Samoan buyer may reasonably be exacting. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Sao Tome and Principe Last Updated: 18 September 2026 TL;DR: Sao Tome and Principe has no national product registration procedure to file into. The Ministry of Health's own Politica Farmaceutica Nacional 2019-2029 states the non-existence of procedures for the approval and registration of medicines, so there is no marketing authorisation to win and no recognition list. The operative gates sit elsewhere: the licensed local importer, customs, and for donor-funded volume the Global Fund quality assurance policy, which India's CDSCO credentials do not satisfy for a non-vaccine injectable. Key Takeaways The framework statute, Lei n.o 09/2018 (Lei Base de Saude), commenced 30 days after publication on 6 June 2018. Article 1(l) defines an Autoridade de Medicamentos but does not establish one, and Article 24 defers pharmaceutical activity to separate legislation we could not find. The absence of a product register is not an inference. The national pharmaceutical policy affirmatively records the non-existence of approval and registration procedures. That is a proven absence, unlike the many items below that we simply could not find. There is no recognised or reference authority list, so asking whether India's CDSCO appears on it is a category error. You cannot be omitted from a list that does not exist. For donor-funded volume the gate is the Global Fund quality assurance policy, not national law. Its stringent-authority test is closed to regulators that were ICH members or observers before 23 October 2015, and India's WHO transitional listed-authority entry is scoped to vaccines. Introduction: What an Injectable Manufacturer in Sao Tome and Principe Actually Has to Clear Most country guides for exporters open by explaining how to register a product. For Sao Tome and Principe that framing collapses at once, because the thing that would do the registering has not been built. The national pharmaceutical policy cites a population of 201,784 on a 2018 INE projection, a WHO AFRO profile gives roughly 219,160 for 2020, and later estimates run higher. We are not choosing between those figures, and neither should a supplier building a volume forecast. The governing instrument is Lei n.o 09/2018, the Lei Base de Saude, published on 6 June 2018 and in force roughly a month later. It repealed the 1980 Codigo Sanitario, the only instrument that had contained detailed pharmaceutical machinery, and replaced it with a deferral: Article 24 states that pharmaceutical activity has its own specific legislation, and Article 50 obliges the Government to issue implementing instruments. Whether any medicines decree has since been enacted we could not establish. That is a not found, not proof either way. What Sets a World-Class Injectable Manufacturer in Sao Tome and Principe Apart What distinguishes a serious supplier is refusing to read an empty register as an open door. There is no marketing authorisation to obtain, which also means there is no regulatory asset to acquire: no certificate, no data exclusivity, nothing stopping the next supplier following you in a month later. The absence of a registration procedure removes your cost of entry and your moat at once, and it is not an affirmative legal permission to import. The constraints that bite sit on the counterparty and the border. Pharmacy and establishment licensing runs through Decreto-Lei 53/78 and Article 47 of Lei 09/2018, which subjects private health units including pharmacies to State licensing. Customs duty is put at 5 to 10 per cent depending on product, with Ministry of Health imports excepted, and the ministry recommends making clearance faster, which implies it is not. What documents an importer must file at that border we could not establish, and we will not invent a checklist. Quality Systems Behind Every Batch Shipped to Sao Tome and Principe Farbe Firma manufactures sterile injectables under WHO-GMP certification with ISO Class 5 aseptic filling in Gujarat, India, supported by in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A and Q1B stability programmes. Every batch ships with a certificate of analysis traceable to retained samples, and we prepare CTD and ACTD dossiers as standard for the 30+ countries we export to. Here that documentation is not a filing requirement. It is the only independent quality evidence anyone in the chain will have. That matters because the policy is candid about the country's own capacity. Quality control is not carried out systematically, samples travel to external laboratories because there is no national quality control laboratory, and inspection is limited to documentary and visual checks. Pharmacovigilance still requires legal cover. Distribution does not meet good storage and distribution practice, particularly for thermolabile medicines, which argues for room-temperature-stable presentations where the molecule allows. Planning a Sao Tome and Principe entry, or weighing a national route against a regional or donor-funded one? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Sao Tome and Principe for Global Buyers The next question is whether a regional regime fills the national gap. It does not. Sao Tome and Principe is not an ECOWAS member, a point worth stating because it is often assumed. It is a founder of ECCAS, but we found no ECCAS medicines harmonisation instrument and no mutual recognition route; the literature describes ECCAS states as unharmonised. CPLP membership brings a cooperation aspiration in Article 12(3) of Lei 09/2018, not a pathway. The country appears on neither the signature nor the ratification list for the African Medicines Agency treaty, and the two are not the same. So the volume worth winning tends to flow through donor channels, where the rules are not Sao Tomean at all. A Global Fund malaria grant reported at around US$6 million is channelled through UNDP, so UN procurement rules and the Global Fund quality assurance policy govern eligibility. That policy requires WHO prequalification, authorisation by a stringent regulatory authority or WHO Listed Authority, or a time-limited Expert Review Panel recommendation. On the agency routes an Indian file fails twice over, and we would rather say so than let a client discover it inside a tender. The two reasons are independent and both easy to miss. The Global Fund's definition limits stringent authorities to those that were ICH members or observers before 23 October 2015, and CDSCO became a standing observer only in 2019. Separately, India's entry on WHO's published transitional listed-authority list carries the scope Vaccines, where Ghana, Nigeria and Tanzania are scoped Medicines. A non-vaccine injectable derives nothing from either. The honest conclusion is the inverse of the intuitive one: the investment that matters is WHO prequalification or an ERP pathway plus a licensed local importer, not a dossier with nowhere to go. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my injectable before it can be sold there? There is no procedure to register into. The Ministry of Health's national pharmaceutical policy states in terms that procedures for approval and registration of medicines do not exist, and lists establishing them among its forward directives. This is one of the very few things here that is a proven absence rather than something we merely could not find. Read it carefully though: no register is not the same as permission to import, because the importer licence, customs and any ad hoc ministerial authorisation remain live and undocumented gates. Is India's CDSCO on a recognised or reference authority list? The question is a category error and we will answer it as one rather than give a tidy yes or no. There is no list of recognised or stringent authorities, because there is no registration procedure for reliance or abridgement to attach to. CDSCO is not on such a list, and equally has not been excluded from one, because exclusion presupposes a list. A named list does bite at the donor layer. What are the registration fees and review timelines? We found none, from any source, in either direction, consistent with there being no registration procedure to charge for. We will not publish a number we cannot support, and you should treat any guide quoting one with suspicion. The only monetary figures we located are a customs duty of 5 to 10 per cent depending on product, with Ministry of Health imports excepted, and fines in the repealed 1980 code. Neither is a registration fee. Who actually buys, and can I appoint a national distributor? The public sector is supplied through the Fundo Nacional de Medicamentos, created by Decreto-Lei 52/98, with a planned transformation into CAME. Whether that has happened we cannot say: the primary policy frames CAME as planned while a secondary page describes it in the present tense, and sources even differ on what the acronym expands to. We are not choosing. On the private side the policy records that pharmacies import for themselves because the country lacks a wholesale distributor company, so your counterparty is likely a single pharmacy or small importer, not a national distributor. In what language should labels and product information be supplied? Portuguese, for labelling and patient information. The policy requires INN presentation on packaging, labels, inserts and promotional material in Portuguese, and complains that dispensed products currently arrive without a Portuguese-language patient leaflet. What we will not tell you is that dossiers must be submitted in Portuguese, because we found no dossier procedure for a language rule to attach to. Two further cautions from the same document: the informal market is described as predominant, and donations other than one named project arrive without criteria safeguarding quality. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Why Farbe Firma is the Leading Injectable Manufacturer in Barbados Last Updated: 16 September 2026 TL;DR: Barbados has historically had no product registration requirement at all - the gate is commercial, not regulatory: an importer's licence, supplier registration with the Barbados Drug Service, a local agent and a place on the national formulary. That is now changing: the Barbados Medical Products Act, 2026 was passed in June 2026 and will introduce marketing authorisation, but as of PAHO's July 2026 report the new Authority was not yet operating and its guidance was still in draft. Key Takeaways The Pharmaceutical Country Profile published by the Barbados Ministry of Health with PAHO/WHO - the most recent available, and dated 2011 - records that legal provisions did not require marketing authorisation for pharmaceutical products, and that no mutual recognition mechanisms were in place. What is required instead is an importer's licence, entry through authorised ports where products may be sampled, and GMP compliance by the manufacturer - including foreign manufacturers, though the same profile notes that Barbados does not publish its GMP requirements. The reference-authority list that actually bites sits one level up, at CARPHA's Caribbean Regulatory System, and India's CDSCO is not on it - but WHO prequalification is expressly an accepted route, and WHO PQ is open to Indian manufacturers. The Barbados Medical Products Act, 2026 creates a Barbados Medical Products Authority that will take over marketing authorisation. Enactment is not commencement, and the commencement position should be verified before anyone plans around it. Introduction: What an Injectable Manufacturer in Barbados Actually Has to Clear Barbados is a market of roughly 280,000 people, and it is one of the more unusual regulatory propositions in the Caribbean. Most country guides written for exporters open by explaining how to register a product. For Barbados that framing has historically been wrong, and an exporter who budgets for a registration dossier may be budgeting for the wrong thing while under-resourcing the thing that actually decides the outcome. According to the Pharmaceutical Country Profile published by the Ministry of Health with PAHO and WHO - the most recent such profile available, and dated 2011 - Barbados did not require marketing authorisation, or product registration, for pharmaceutical products placed on its market, and no mutual recognition mechanisms were in place. It lists inspection, import control, licensing and quality control as functions the authority did perform. We flag the date deliberately: fifteen years is a long time, and a new Act has since passed. What Sets a World-Class Injectable Manufacturer in Barbados Apart If there is no dossier queue, what is there? On the evidence, a sequence: a licensed Barbadian importer; the manufacturer registered as a supplier with the Barbados Drug Service; a local agent, because the country profile records that international companies are required to bid through one; the product listed on the Barbados National Drug Formulary, some seven hundred medicines selected by a Drug Formulary Committee advisory to the Minister; and then success in a Drug Service competitive tender. Note the noun carefully - companies are registered with the Drug Service, not products. Conflating supplier registration with product registration is the single commonest error in this market. Two features of that tender reward a manufacturer who can document itself. The profile records that a process exists to ensure the quality of products procured for the public sector, including prequalification of both products and suppliers, and that medicines are tested for public procurement prequalification - but not for product registration, which neatly locates where the real quality gate sits. It also records that there are no legal provisions giving priority to locally produced goods, which is favourable to an importer, and that at the time of writing 97.25 per cent of pharmaceuticals were supplied by foreign companies registered with the Drug Service. Quality Systems Behind Every Batch Shipped to Barbados Farbe Firma manufactures sterile injectables under WHO-GMP certification at ISO Class 5 aseptic filling, with in-house HPLC, GC, LAL endotoxin and Karl Fischer testing and ICH Q1A/Q1B stability programmes, and every batch ships with a certificate of analysis traceable to retained samples. That matters more here than in a registration market, because Barbados has no national quality-control laboratory of its own: the country profile records that testing is contracted out, naming the Caribbean Regional Drug Testing Laboratory and Experchem in Canada. One requirement clearly does reach a foreign manufacturer. The profile records legal provisions requiring manufacturers, domestic and international alike, to comply with Good Manufacturing Practices - while noting in the same passage that GMP requirements are not published by the government. In practice a real obligation is measured against an unpublished standard, so the applicable expectation has to be established in dialogue with the Barbados Drug Service, and a supplier arriving with WHO-GMP certification and a complete site master file is arguing from a much stronger position than one who is not. Planning a Barbados entry, or weighing a national route against a regional or donor-funded one? Speak to our regulatory team Why Farbe Firma is the Trusted Injectable Manufacturer in Barbados for Global Buyers The lesson the Caribbean teaches repeatedly is that when the national gate is open, the exclusion is usually one level up. Barbados has no national list of recognised regulators, because it has had no registration system to attach one to. But a named reference-authority list does exist regionally, and an Indian manufacturer will meet it: CARPHA's Caribbean Regulatory System conducts abbreviated review only for products already approved by a designated reference authority - the PAHO regional reference authorities, the European Union or the United States - and India is not among them. There is, however, an explicit way through, and it is the most commercially important sentence we can offer. CARPHA lists WHO prequalification alongside those agencies as a qualifying basis for review, and WHO prequalification is fully open to Indian manufacturing sites. Two honest limits belong with it: CARPHA's review is confined to products on the current WHO Essential Medicines List or the PAHO Strategic Fund list, and CARPHA only recommends favourably reviewed products to member states for consideration, leaving the decision national. The forward-looking picture matters just as much. PAHO reported on 30 July 2026 that, following the passing of the Barbados Medical Products Act in mid-June, officials were working on draft guidance for product registration, draft accompanying regulations, staffing and systems for the new Authority, and had explored the use of reliance and recognition approaches. A Barbadian list of trusted regulators may well emerge from that work. None has been published, and which authorities will appear on it is not known - including to Barbados. What we can do is have a WHO-GMP file, a CTD/ACTD dossier and a prequalification pathway ready for the moment it is. Explore Farbe Firma: Products / Global Reach / About Us Frequently Asked Questions (FAQ) Do I need to register my product with a Barbados medicines agency? Historically, no - what is required is an importer's licence, with entry through authorised ports where products may be sampled and inspected. The caveat is important: the Barbados Medical Products Act, 2026 will introduce marketing authorisation under a new Authority, which as of July 2026 was not yet operating. Confirm the current position before you commit. Is India on any Barbados list of approved source countries? There is no such Barbadian list, because there has been no registration system to attach one to. At regional level there is a list and India is not on it: CARPHA's Caribbean Regulatory System names the PAHO reference authorities, the EU and the USA. CDSCO approval alone therefore does not unlock the CARPHA route, and it is worth adding that India's CDSCO appears on WHO's transitional listed-authority list with scope limited to vaccines, so a "stringent authority" argument built on it will not survive scrutiny for a non-vaccine injectable. Will WHO Prequalification actually help me in Barbados? For the CARPHA route, demonstrably yes - CARPHA expressly lists WHO prequalification alongside the reference agencies as a qualifying basis for abbreviated review, and that is the documented mechanism by which a product approved in India can enter the CARICOM abbreviated pathway. Whether Barbados itself gives WHO PQ any standalone weight is not documented, and since Barbados has had no registration system the question may not yet be a meaningful one. What dossier format is required, and do I need a WHO CPP? We found no Barbadian instrument prescribing CTD, ACTD or eCTD, and none requiring a WHO Certificate of a Pharmaceutical Product. That is a "not found" rather than a proven absence, and it is partly explained by there being no registration procedure yet to prescribe a format. Expect it to be settled by the draft guidance PAHO reports is being prepared. We could not establish which pharmacopoeias Barbados recognises, and we would not assume BP merely from the legal heritage. How do I find current Drug Service tenders and supplier registration forms? Directly, unfortunately. Throughout our research the Barbados Drug Service website was returning a server error rather than a page, so current tender documents, supplier registration forms, formulary editions and volumes could not be obtained from published sources. Prospective suppliers will need to approach the Drug Service and the Ministry of Health and Wellness directly. Note also that Barbados operates a general import licensing system under the Miscellaneous Controls Act Cap. 329 administered by the trade ministry, separate from any health requirement. Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India. Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog

Discover the best company to work for in the pharmaceutical industry. Explore job listings and job titles at Farbe Firma Pvt. Ltd. in Ankleshwar, Gujarat. Job Listings At Farbe Firma, you’re more than an employee—you are part of a mission to transform global healthcare. As a member of our team, you’ll work in state‐of‐the‐art facilities that adhere to WHO-GMP standards and partner with experts who push the boundaries of innovation in sterile injectable manufacturing. We export to over 30 countries, ensuring your work has real, positive impact on patients worldwide. We value learning, integrity, and scientific excellence, offering opportunities for growth, collaboration, and development in a culture that demands quality, but supports you every step of the way. Share Your CV and Join Farbe Firma Pvt Ltd's Growing Team of Pharmaceutical Professionals hr@farbefirma.com & info@farbefirma.com Purchase Executive View Job Purchase Manager View Job QC Micro View Job RO Operator View Job Packing Officer View Job QA Validation View Job HR Manager View Job HR Specialist View Job Jobs for Fresher View Job HR Executive View Job Ampoule Filling line Operator View Job Vial Line Operator View Job Share Your CV and Join Farbe Firma Pvt Ltd's Growing Team of Pharmaceutical Professionals hr@farbefirma.com & info@farbefirma.com

Browse 245+ WHO-GMP sterile injectable formulations from Farbe Firma — strengths, packing & therapeutic categories. Bulk export & dossier support. Formulation List Therapeutic Category Filter by Product Name Alpha Beta Arteether Injection 75 mg/ml 1 ml, 2 ml, 3 ml Antimalarials & Antiprotozoals https://www.farbefirma.org/product/alpha-beta-arteether-injection Read More Amikacin Sulphate Injection 250 mg/ml 2 ml Antibiotics https://www.farbefirma.org/product/amikacin-sulphate-injection Read More Analgin Injection (Metamizole/Dipyrone) 100 mg/ml 2 ml, 5 ml Antihistamines / Antiallergics / Antiasthmatic https://www.farbefirma.org/product/analgin-injection Read More Artemether Injection 40 mg/ml, 80 mg/ml 1 ml Antimalarials & Antiprotozoals https://www.farbefirma.org/product/artemether-injection Read More Atropine Sulphate Injection 0.6 mg/ml, 1 mg/ml 1 ml Antidotes & Detoxifying Agents https://www.farbefirma.org/product/atropine-sulphate-injection Read More Bacteriostatic Water for Injection 0.9%, 1.1% 2 ml, 10 ml, 20 ml Electrolytes & Diluents https://www.farbefirma.org/product/bacteriostatic-water-for-injection Read More Citicoline Sodium Injection 125 mg/ml, 250 mg/ml 4 ml, 5 ml CNS / Anticonvulsants / Anxiolytics https://www.farbefirma.org/product/citicoline-sodium-injection Read More Clindamycin Injection 150 mg/ml 1 ml, 2 ml, 4 ml, 6 ml, 50 ml Antibiotics https://www.farbefirma.org/product/clindamycin-injection Read More Co Trimoxazole Injection 80 mg + 400 mg 5 ml, 10 ml Antibiotics https://www.farbefirma.org/product/co-trimoxazole-injection Read More Colistimethate Sodium for Injection 1 MIU, 2 MIU Lyo Vial Antibiotics https://www.farbefirma.org/product/colistimethate-sodium-for-injection Read More 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 ... 24

Leading WHO-GMP manufacturer of Cerebroprotein Hydrolysate for Injection . Available in 60 mg . Global exporter to Africa, CIS & Asia. Contact for CDMO & bulk supply. < Back Cerebroprotein Hydrolysate for Injection Strength: 60 mg Fill Volume: Lyo Vial Therapeutic Catagory: Other Product Name: Cerebroprotein Hydrolysate for Injection For More details please visit: https://www.farbefirma.org/products or https://www.farbefirma.org/contact Previous Next